Skip to main content
. 2018 Oct 5;9(78):34838–34854. doi: 10.18632/oncotarget.26208

Figure 1. Number of EVs and oncogenic miRNAs are increased in the plasma of patients with OSCC.

Figure 1

(A) Total number of EVs in the plasma of patients with OSCC and matched controls were measured by a Nanoparticle Tracking analysis (Nanosight) (n = 34). Each measurement was done in triplicate. (B) The average size of exosomes was measured by Nanoparticle Tracking analysis (NTA) in control and OSCC patients. (C) The graph is representative of small RNA of EVs isolated from plasma of patients with OSCC as analyzed by BioAnalyzer. (D–H) Signature of plasma miRNAs in patients with OSCC and controls was assessed with a TaqMan miRNA qPCR assay for quantification of miR-21, miR-155, miR-27a, miR-27b, miR-16. miR-Cel-39 was used as exogenous normalizer. (I, J) Expression levels of miR-27a, miR-27b, and miR-21 was identified in EV fraction and non-EV fraction of plasma starting from same amount of plasma (100 μl) with a TaqMan miRNA qPCR assay (n = 10 control, 10 OSCC patients). After isolation of EVs RNase A treatment at final concentration of 5 μg/mL for 30 min was done. (*indicates p < 0.05 versus control).